Literature DB >> 7751717

The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome.

E Gratacós1, P J Torres, J Vidal, E Antolín, J Costa, M T Jiménez de Anta, V Cararach, P L Alonso, A Fortuny.   

Abstract

A prospective study of parvovirus B19 infection during pregnancy was conducted at a large teaching hospital in Barcelona, Spain. Women (1610) who were < 28 weeks pregnant at enrollment were screened for parvovirus infection. The prevalence of IgG positivity was 35.03% (564/1610). The incidence of acute infection during pregnancy was 3.7% (60/1610). There were five abortions among the B19-infected women but only one was caused by parvovirus, as assessed by histologic examination and polymerase chain reaction assay. The incidence of fetal loss caused by parvovirus was, therefore, 1.66% (1/60). The remaining 55 pregnancies were uneventful, and at 1 year of age, none of the infants had serious abnormalities. The incidence of vertical transmission of infection was estimated at 25%. This study provides evidence that although acute parvovirus infection may occur relatively commonly during pregnancy, an adverse fetal outcome is a rare complication.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751717     DOI: 10.1093/infdis/171.5.1360

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.

Authors:  J A Jordan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

Review 2.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

3.  Quebec's safe working conditions for a Safe Maternity Experience program: survey of consultant physicians and human parvovirus B19 in Montreal-Centre.

Authors:  A T Koutsavlis; J F Boivin; R Simard; M Rossignol
Journal:  Can J Public Health       Date:  2000 Jul-Aug

4.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

Review 5.  Parvovirus B19 infection in human pregnancy.

Authors:  R F Lamont; J D Sobel; E Vaisbuch; J P Kusanovic; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2010-10-13       Impact factor: 6.531

6.  Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydrops.

Authors:  M Zerbini; M Musiani; G Gentilomi; S Venturoli; G Gallinella; R Morandi
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

7.  Placental cellular immune response in women infected with human parvovirus B19 during pregnancy.

Authors:  J A Jordan; D Huff; J A DeLoia
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

8.  Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany.

Authors:  M Enders; A Weidner; G Enders
Journal:  Epidemiol Infect       Date:  2006-10-26       Impact factor: 2.451

9.  Parvovirus B19 during pregnancy: a review.

Authors:  Elsa Giorgio; Maria Antonietta De Oronzo; Irene Iozza; Angela Di Natale; Stefano Cianci; Giovanna Garofalo; Anna Maria Giacobbe; Salvatore Politi
Journal:  J Prenat Med       Date:  2010-10

Review 10.  Evolutionary aspects of Parvovirus B-19V associated diseases and their pathogenesis patterns with an emphasis on vaccine development.

Authors:  Piyanki Das; Koustav Chatterjee; Nabanita Roy Chattopadhyay; Tathagata Choudhuri
Journal:  Virusdisease       Date:  2019-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.